Cook General Biotechnology

CookGBT.com

Cook General BioTechnology, LLC (CGBT), was formed after Cook Medical purchased the private company, General BioTechnology, LLC., in the spring of 2012. CGBT is actively involved in cell therapy and has assisted in the development and refinement of advanced cryopreservation and banking procedures for differing cell and tissue types.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CYTODYN ANNOUNCES FIRST SITE IN THE SOUTHEASTERN USA TO ENROLL PATIENTS IN PHASE 2 CORONAVIRUS TRIAL

Proactive Investors | April 08, 2020

news image

The Novant Health network cares for around 5 million patients a year at nearly 700 locations, including 15 hospitals and hundreds of outpatient facilities and physician clinics. CytoDyn Inc (OTCQB:CYDY), the late stage biotech, said partner Novant Health has started enrolling patients in the company's Phase 2 randomized clinical trial using leronlimab for coronavirus (COVID-19) patients with mild-to-moderate symptoms. Novant Health is the second trial site in the USA and the first site in th...

Read More

Industrial Impact

BEIGENE ANNOUNCES LAUNCH OF BIOISLAND INNOVATION CENTER

BeiGene | December 27, 2021

news image

BeiGene, a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced the official launch of the BeiGene Bioisland Innovation Center in Guangzhou, China to enable scientists and entrepreneurs to accelerate development of highly differentiated, cutting-edge medical innovations. The BIC is an innovator-centric incubator built on BeiGene’s goal of supporting exploration of new paths to meet patient needs around the world. Read More

Industrial Impact

PSYCHECEUTICAL COMPLETES ACQUISITION BY BLUE WATER VENTURES INTERNATIONAL

Blue Water Ventures International | January 20, 2022

news image

Psycheceutical, Inc. a biotechnology company dedicated to the development and commercialization of psychedelic medicines, announced the company has been fully acquired by Blue Water Ventures International, Inc. “We are thrilled that this deal has closed and that Psycheceutical is now a wholly-owned subsidiary of a publicly-listed company and has secured important near-term capital to pursue our growth plans. We will immediately begin the next steps of o...

Read More

MedTech

QIAGEN LAUNCHES SYNDROMIC TEST FOR QIASTAT-DX DEVICE TO COMBAT GLOBAL MONKEYPOX HEALTH EMERGENCY

QIAGEN | August 16, 2022

news image

QIAGEN N.V. announced the launch of the QIAstat-Dx Viral Vesicular Panel RUO, the first syndromic test to differentiate between monkeypox and five other pathogens which cause similar symptoms. The new panel ­– currently for research use only comes in cartridge form to run on QIAGEN’s QIAstat-Dx automated syndromic testing devices. It tests for the two known forms of monkeypox virus herpes simplex virus 1 HSV2, human herpesvirus 6 (HH6), varicella-zoster virus and e...

Read More
news image

CYTODYN ANNOUNCES FIRST SITE IN THE SOUTHEASTERN USA TO ENROLL PATIENTS IN PHASE 2 CORONAVIRUS TRIAL

Proactive Investors | April 08, 2020

The Novant Health network cares for around 5 million patients a year at nearly 700 locations, including 15 hospitals and hundreds of outpatient facilities and physician clinics. CytoDyn Inc (OTCQB:CYDY), the late stage biotech, said partner Novant Health has started enrolling patients in the company's Phase 2 randomized clinical trial using leronlimab for coronavirus (COVID-19) patients with mild-to-moderate symptoms. Novant Health is the second trial site in the USA and the first site in th...

Read More
news image

Industrial Impact

BEIGENE ANNOUNCES LAUNCH OF BIOISLAND INNOVATION CENTER

BeiGene | December 27, 2021

BeiGene, a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced the official launch of the BeiGene Bioisland Innovation Center in Guangzhou, China to enable scientists and entrepreneurs to accelerate development of highly differentiated, cutting-edge medical innovations. The BIC is an innovator-centric incubator built on BeiGene’s goal of supporting exploration of new paths to meet patient needs around the world. Read More

news image

Industrial Impact

PSYCHECEUTICAL COMPLETES ACQUISITION BY BLUE WATER VENTURES INTERNATIONAL

Blue Water Ventures International | January 20, 2022

Psycheceutical, Inc. a biotechnology company dedicated to the development and commercialization of psychedelic medicines, announced the company has been fully acquired by Blue Water Ventures International, Inc. “We are thrilled that this deal has closed and that Psycheceutical is now a wholly-owned subsidiary of a publicly-listed company and has secured important near-term capital to pursue our growth plans. We will immediately begin the next steps of o...

Read More
news image

MedTech

QIAGEN LAUNCHES SYNDROMIC TEST FOR QIASTAT-DX DEVICE TO COMBAT GLOBAL MONKEYPOX HEALTH EMERGENCY

QIAGEN | August 16, 2022

QIAGEN N.V. announced the launch of the QIAstat-Dx Viral Vesicular Panel RUO, the first syndromic test to differentiate between monkeypox and five other pathogens which cause similar symptoms. The new panel ­– currently for research use only comes in cartridge form to run on QIAGEN’s QIAstat-Dx automated syndromic testing devices. It tests for the two known forms of monkeypox virus herpes simplex virus 1 HSV2, human herpesvirus 6 (HH6), varicella-zoster virus and e...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us